11 mar: Cool køkkentrends
16 mar: SKAGEN Fondene: Kan Europa tåle en strammere pengepolitik?
16-03-2011 09:45:51

Fiscal year 2010: Dräger's net sales and earnings grow steeply

Drägerwerk AG & Co. KGaA /

Fiscal year 2010: Dräger's net sales and earnings grow steeply

Processed and transmitted by Thomson Reuters.

The issuer is solely responsible for the content of this announcement.

  • Record net sales of around EUR 2.18 billion

  • Net profit more than tripled

  • Dividend to rise by EUR 0.79 per share

Lübeck - 2010 was an outstanding year for Drägerwerk AG & Co. KGaA. Order intake rose by 4.1 percent (net of currency effects) to EUR 2,145.4 million (2009: EUR 1,978.3 million). Net sales went up by 9.5 percent (net of currency effects) to a record EUR 2,177.3 million (2009: EUR 1,911.1 million), and EBIT by 140.6 percent to EUR 192.8 million (2009: EUR 80.1 million). The EBIT margin increased from 4.2 percent to 8.9 percent, coming in at the upper limit of the bandwidth of 8 percent to 9 percent the Company had forecast in October 2010. Net profit rose disproportionately, tripling to EUR 104.8 million (2009: EUR 32.5 million).

 

Turnaround target met one year earlier than planned

"Net sales and earnings developed very positively thanks to an unexpectedly high order intake in the fourth quarter of 2010, the continuing positive development in the Americas and Asia/Pacific regions, the launch of our new products and favorable currency effects. And the turnaround program also had an extremely positive impact," explained Stefan Dräger, Chairman of the Executive Board of Drägerwerk Verwaltungs AG. The program aimed at saving costs and increasing efficiency contributed an additional EUR 41.0 million to earnings compared to the previous year. Dräger therefore increased its profitability before implementation costs by a total of EUR 107.3 million in 2010 compared to the year 2008. The original plan was to achieve sustainable savings of EUR 100 million as from 2011.

 

Medical division

In fiscal year 2010, order intake in the medical division went up by 3.5 percent (net of currency effects) to EUR 1,441.9 million (2009: EUR 1,339.6 million). Net sales rose by 12.4 percent (net of currency effects) to EUR 1,472.0 million (2009: EUR 1,260.9 million). EBIT soared by 143.3 percent to EUR 186.6 million (2009: EUR 76.7 million), and the EBIT margin of 12.7 percent was significantly up on the previous year's value of 6.1 percent.

 

Safety division

Order intake in the safety division totaled EUR 731.7 million, 5.1 percent (net of currency effects) higher than in the previous year (2009: EUR 665.9 million). The division's net sales rose by 3.8 percent (net of currency effects) to EUR 733.8 million year on year (2009: EUR 676.9 million). EBIT in the safety division doubled to EUR 61.0 million (2009: EUR 30.2 million) as a result of a higher business volume and gross margin and lower expenses from the business in deep sea diving systems. The EBIT margin went up to 8.3 percent (2009: 4.5 percent). In the previous year, impairment losses of EUR 30.0 million were recognized on deep sea diving systems.

 

Equity ratio rises to 32.2 percent

The equity base of the Company improved significantly after it had dropped to 20.9 percent on account of the buyback of the 25 percent Siemens share in the previous Dräger Medical AG & Co. KGaA as of December 31, 2009. In 2010, equity grew by EUR 242.8 million to EUR 636.6 million while other non-current and current financial liabilities dropped significantly by EUR 239.6 million. This increased Dräger Group's equity ratio to 32.2 percent. The capital increase carried out in June 2010, net profit of EUR 104.8 million and the option component, which was converted into an equity instrument in August 2010, particularly contributed to this development.

 

Dividend to rise by EUR 0.79 per share

In view of the positive earnings development and the equity ratio rising to 32.2 percent, the Executive Board and Supervisory Board will propose to the annual shareholders' meeting on May 6, 2011, to increase the dividend by EUR 0.79 per share compared to the previous year. EUR 1.13 are to be distributed per common share (2009: EUR 0.34) and EUR 1.19 per preferred share (EUR 0.40). This corresponds to the distribution rate of 30 percent to shareholders and participation certificate holders that had been announced in the previous year.

 

 

Outlook: Order intake and net sales increase

Dräger anticipates that order intake will grow at least as fast as the entire global economy (World Bank forecast: +3.3 percent) in fiscal year 2011. This expectation is based on the assumptions that the economy in Europe will stabilize, that the economy in the USwill continue to recover, that the market will continue to grow in the emerging countries and that exchange rates will remain the same. Net sales growth in 2011 is likely to fall one to two percentage points short of order intake growth, as net sales in 2010 profited from above-average order intake in the fourth quarter of 2009.  

Dräger expects a Group EBIT margin between 7.5 percent and 8.5 percent (2010: 8.9 percent) in fiscal year 2011 on account of larger investments in product development as well as the improved sales organization and Group-wide IT structure. In the medium term, the Company aims at growing stronger than the market and achieving an EBIT margin of at least 10 percent.

 

 

Key figures (in € million)

  2010 2009 Change

Group

     
Order intake 2,145.5 1,978.3 +8.5 %
Net sales 2,177.3 1,911.1 +13.9 %
EBIT 192.8 80.1 +140.6 %
EBIT margin 8.9 % 4.2 %  
Net profit 104.8 32.5 +222.8 %
Earnings per preferred share (€) 6.25 1.20 +420.8 %
Earnings per common share (€) 6.19 1.14 +443.0 %
Research and development costs 148.4 149.4 -0.7 %
Cash flow from operating activities 219.1 193.5 +13.3 %
Net financial debt 90.3 374.4 -75.9 %
Investments 55.8 128.3 -56.5 %
Capital employed 833.4 709.1 +17.5 %
ROCE 23.1 % 11.3 %  
Dividend per preferred share (€) 1.19 0.40  
Dividend per common share (€) 1.13 0.34  
DVA 114.5 -1.8  
Employees 11,291 11,071 +2.0 %

 

     

Medical division

     
Order intake 1,441.9 1,339.6 +7.6 %
Net sales 1,472.0 1,260.9 +16.7 %
EBIT 186.6 76.7 +143.3 %
EBIT margin 12.7 % 6.1 %  
Research and development costs 101.1 107.8 -6.2 %
Cash flow from operating activities 178.4 153.1 +16.5 %
Capital employed 514.7 546.6 -5.8 %
ROCE 36.3 % 14.0 %  
  2010 2009 Change
DVA 136.5 23.6  
Employees 6,386 6,305 +1.3 %
       

Safety division

     
Order intake 731.7 665.9 +9.9 %
Net sales 733.8 676.9 +8.4 %
EBIT 61.0 30.2 +102.3 %
EBIT margin 8.3 % 4.5 %  
Research and development costs 43.9 39.3 +11.9 %
Cash flow from operating activities 74.3 73.8 +0.6 %
Capital employed 181.6 190.1 -4.4 %
ROCE 33.6 % 15.9 %  
DVA 43.1 9.6  
Employees 4,409 4,336 +1.7 %

 

 

Disclaimer

This press release contains forward-looking statements regarding the future development of the Dräger Group. These forward-looking statements are based on the current expectations, presumptions, and forecasts of the Executive Board as well as the information available to it to date and have been prepared to the best of its knowledge and belief. No guarantee or liability for the occurrence of the future developments and results specified can be assumed in respect of such forward-looking statements. Rather, the future developments and results are dependent on a number of factors. They entail risks and uncertainties beyond the Company's control and are based on assumptions which could prove to be incorrect. Notwithstanding any legal requirements to adjust forecasts, we assume no obligation to update the forward-looking statements contained in this report. You will find all other financial dates on our website at www.draeger.com under Investor Center/Financial Calendar.

 

 

Contact

 

Corporate Communications:

Burkard Dillig

Tel. +49 451 882-2185

burkard.dillig@draeger.com

 

Investor Relations:

Vanina Hoffmann

Tel. +49 451 882-2685

vanina.hoffmann@draeger.com

 

 

Drägerwerk AG & Co. KGaA     

Moislinger Allee 53-55

23542 Lübeck, Germany

www.draeger.com

 

Press release (PDF)

--- End of Message ---

Drägerwerk AG & Co. KGaA

Moislinger Allee 53-55 Lübeck Germany

Listed: Freiverkehr in Börse Stuttgart,

Prime Standard in Frankfurter Wertpapierbörse,

Regulierter Markt in Frankfurter Wertpapierbörse,

Regulierter Markt in Bayerische Börse München,

Regulierter Markt in Börse Berlin,

Regulierter Markt in Hanseatische Wertpapierbörse zu Hamburg,

Regulierter Markt in Börse Düsseldorf,

Regulierter Markt in Niedersächsische Börse zu Hannover;

This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients.

The owner of this announcement warrants that:

(i) the releases contained herein are protected by copyright and other applicable laws; and

(ii) they are solely responsible for the content, accuracy and originality of the

information contained therein.

Source: Drägerwerk AG & Co. KGaA via Thomson Reuters ONE

HUG#1497230

Opret kommentar

Relateret debat

  • 1 uge
  • 1 måned
  • 1 År
18 okt
OMXC20
Data herunder er lavet på C20 Cap og C20 vægtet til at passe til C20 Cap i 2010 og 2011.   Siden den..
66
16 okt
 
Jeg skriver lige det her indlæg fordi det er 5. gang som investor jeg oplever en af de her lidt stør..
56
16 okt
 
Kære Alle   Jeg takker Jer alle for en god tid her, jeg erkender at have tabt, selvom jeg holdt mig ..
36
17 okt
VWS
Normal 0 21 false false false DA X-NONE X-NONE ..
28
17 okt
I:SP500
  Hvorfor aktiemarkedet ikke er blevet for dyrt   I mit indlæg vedr. aktie- og vækstkrise beskrev je..
21
16 okt
I:SP500
  @bgadk – enig i, at en moderat inflationær politik der holder deflations-spøgelset nede, er præcis..
20
20 okt
VELO
Match, så har jeg set lidt på mine handler og depoter.   Må begynde med at konkludere, at mit handel..
17
20 okt
VELO
Tvivler på at du får ret. Aktieanalytikerne siger allerede før godkendelsen en KORTSIGTET kurs på 2..
17
16 okt
OMXC20
Med reference til mit indlæg af 10.07.2014 emne nummer 280903   Dengang i juli var der uro på marked..
16
21 okt
VWS
Hvis du var en ludo brik var du så ikke slået hjem nu ???
14

Høreapparater/Bernstein: Siemens-køb muligt for både GN og WDH

22-10-2014 16:40:02
Det er ikke helt utænkeligt, at en af de to store danske høreapparatproducenter, William Demant Holding og GN Resound, vil kunne absorbere et opkøb af tyske Sie..

Genmab venter royalties fra Arzerra-salg på 27 mio. kr. i Q3

22-10-2014 13:11:49
Genmab regner med at modtage royalties på cirka 27 mio. kr. fra Glaxosmithklines salg af Arzerra i tredje kvartal.Det meddeler Genmab i forbindelse med, at Glax..

Nordea Danmark sværger troskab til Swipp

22-10-2014 11:07:17
Selvom storbanken Nordea nu sætter gang i en storstilet it-offensiv, der skal strømline den pannordiske banks systemer på tværs af landegrænser, så er der ingen..

Mest læste nyheder

  • 24 timer
  • 48 timer
  • 1 uge
1
Bavarian/Nordea: Ebola-aftale er veltimet, værdifuld og vigtig
2
Bavarian overrasker med foreløbigt regnskab
3
Bavarian hopper på ebola meddelse
4
Aktier/åbning: Bavarian tordner i vejret
5
Al-Qaeda blæser til kamp mod vestlige olietankere
Euroinvestor i andre lande: Euroinvestor.com | Euroinvestor.se | Euroinvestor.no | Euroinvestor.fr | Forexinvestor.com| Wisselkoersen.nl | Valuta.se | Valutaveksel.no | Divisas.es | Valute.it
Copyright Euroinvestor A/S 2014  Disclaimer Privatlivspolitik
Aktieinformation leveres af Interactive Data.
Data er forsinket 15-20 minutter iht. de enkelte børsers regler om videredistribution.
 
23. oktober 2014 06:31:43
(UTC+01:00) Brussels, Copenhagen, Madrid, Paris
Version: LiveBranchBuild_20141015.1 - EUROWEB6 - 2014-10-23 06:31:43 - 2014-10-23 06:31:43 - 1 - Website: OKAY

Når du besøger Euroinvestor.dk accepterer du, at der anvendes cookies, som vi og vores samarbejdspartnere benytter til funktionalitet, statistik og markedsføring. Læs mere om cookies på Euroinvestor.dk her

x